35results about How to "Lower LDL levels" patented technology

The invention is for the combination of EDTA, cystine, selenium, Vitamin C, Vitamin E, and zinc for anti-thrombotic effect and for the effect of restoring platelet aggregation, an integral component of thrombus formation, to normal and for the monitoring of the response to therapy with the combination. Methods for use of the components and method for performing the monitoring are included. The combination and method are particularly efficacious for vascular deficiency ailments including atherosclerotic vascular disease, reduction of ischemic cerebal event, complications from surgical procedures including restenosis, neurogenerative disease, and erectile disfunction, and vascular deficiency resulting from etiology of sepsis and chronic infection.

The invention discloses grapefruit honey tea with Pu-er components. The grapefruit honey tea is composed of, by weight, 15-20 parts of Pu-er tea leaves, 15-20 parts of honey, 16-26 parts of grapefruit pulp, nine to 14 parts of grapefruit peels, 10-20 parts of lemon pulp, five to ten parts of lemon peels, 10-20 parts of passion fruit pulp, five to ten parts of passion fruit peels, salt accounting for five to nine percent of the weight of the lemon peels, the passion fruit peels and the grapefruit peels and rock candy accounting for three to five percent of the weight of the lemon peels, the passion fruit peels and the grapefruit peels. The invention further discloses a preparation method of the grapefruit honey tea with the Pu-er components. The peels are shredded, are cured with the salt and are smashed into particles, the rock candy is added to the peels for decoction, and peel juice is obtained. The Pu-er tea leaves are soaked in alkaline mineral water, fermenting and squeezing are carried out to obtain Pu-er tea juice and tea grounds. The tea juice is steamed to collect tea juice steam and gas, the honey is added to the cooled tea juice, and honey tea juice is obtained. The pulp is smashed to be evenly mixed with the peel juice and the honey tea juice, heat preservation and cooling are carried out, and the grapefruit honey tea is obtained.

The invention relates to a preparation method and application of an Aleuritopteris argentea Fee extract. The preparation method includes: extracting Aleuritopteris argentea Fee, then performing high-speed counter-current chromatography, macroporous adsorption resin and other chromatography purification to obtain an Aleuritopteris argentea Fee extract B and an Aleuritopteris argentea Fee extract C, mixing the Aleuritopteris argentea Fee extract B with the Aleuritopteris argentea Fee extract C in certain proportion, thus obtaining the Aleuritopteris argentea Fee extract, which can be combined with a pharmaceutically acceptable carrier or other suitable excipients so as to be prepared into oral medication dosage forms according to conventional methods. The Aleuritopteris argentea Fee extract can be used for preparing drugs for preventing and treating diabetes.

The Chinese medicine for curing fatty liver is made up by using 12 Chinese medicinal materials of bupleurum root, ginseng, notoginseng, capillaris, Chinese angelica root and others through the processes of grinding, decocting, making paste, granulating and tableting. Its therapeutic effect is obvious, and it has no toxic side effect.

This invention encompasses methods for manufacturing purified, high molecular weight sulfated polysaccharide compositions that inhibit pancreatic cholesterol esterase and lower cholesterol in the blood stream.

The invention provides sea salt nuts and a processing method thereof. Compared with the prior art, with honey, a peppermint extracting liquid, a broccoli extracting liquid and a hawthorn extracting liquid, the sea salt nuts not only have a more refreshing and more delicious mouth feel, reduce the problem of excessive internal heat, but also promote fat metabolism, reduce fat accumulation, promotedigestion, moisten intestines, relax bowels, and reduce obesity. The method solves the problem that people who are afraid of obesity and high in blood fat hardly dare eat nuts. By controlling baking temperature and time, the sea salt nuts are sufficient in flavoring, and are crisp but not hard. Moreover, the method firstly performs enzyme deactivation, then controls the raw materials of syrup, andthen performs baking, so that not only the nuts are crisper, but also the sea salt adheres to the nuts more firmly.

The invention, in accordance with the theoretical guidance of traditional Chinese medicine prescription, provides a pharmaceutical composition of berberine and a liquorice root extract as well as berberine and glycyrrhizic acid. Compared with single administration, the pharmaceutical composition disclosed by the invention has obvious advantages in the aspect of improving blood glucose, glycated serum protein and insulin levels of a mouse with diabetics, and the pharmaceutical composition has a good synergistic effect; in the aspect of improving lipid metabolism, reducing serum glutamic pyruvic transaminase (ALT) and glutamic oxalacetic transaminase (AST) levels and the like, the pharmaceutical composition also has a good effect, and the pharmaceutical composition has a synergistic effect; and in addition, the pharmaceutical composition is capable of significantly reducing a serum total creatinine (Cre) level and is capable of effectively improving renal functions. Therefore, the pharmaceutical composition can be used for preventing and/or treating diabetics and complications thereof; and the pharmaceutical composition has positive practical significance to the development of medicine.

The invention relates to a preparation method for a Picris japonica extract and application thereof. The preparation method includes: extracting Picris japonica, conducting high speed counter current chromatography, polyamide and other chromatography purification to obtain a Picris japonica extract B and a Picris japonica extract C, and mixing the Picris japonica extract B with the Picris japonica extract C in certain proportion so as to obtain the Picris japonica extract, which can be combined with a pharmaceutically acceptable carrier or other suitable excipients so as to be prepared into oral medication dosage forms according to conventional methods. The Picris japonica extract can be used for preparing drugs for prevention and treatment of diabetes.

The invention relates to a pharmaceutical composition used for treating diabetes. The pharmaceutical composition is prepared by taking nuciferine, cucurbitacin E, hemiphragma heterophyllum glucoside B, and clerodendrin A as drug substances via mixing. Different dosage forms can be obtained via conventional pharmaceutical technology. Defects of the prior art are avoided; and the pharmaceutical composition is used for treating diabetes.

The invention relates to a medicine composition for treating diabetes. The medicine composition comprises oroxin A, cucurbitacine E, hemiphroside B and clerodendrin A in proportion; and various dosage forms can be manufactured according to a conventional preparation technology. The medicine composition overcomes the defects in the prior art; and the medicine composition for treating the diabetes is provided.

The invention relates to a pharmaceutical composition used for treating diabetes. The pharmaceutical composition is prepared by taking justicidin A, hinokiflavone, hemiphragma heterophyllum glucoside B, and clerodendrin A as drug substances via mixing. Different dosage forms can be obtained via conventional pharmaceutical technology. Defects of the prior art are avoided; and the pharmaceutical composition is used for treating diabetes.

The invention relates to a pharmaceutical composition used for treating diabetes, and a preparation method thereof. The pharmaceutical composition comprises following raw materials, by weight, 2 to 5 parts of berberis, 3 to 5 parts of ammoniac, 1 to 4 parts of spiraea alpine, 3 to 8 parts of lepisorus clathratus ching, and 1 to 3 parts of lasurite. The preparation method comprises following steps: the raw materials above are smashed, and sieved using 80 to 200 meshes sieves; and an obtained mixture is made into pills, or the pharmaceutical composition is obtained via extraction of the obtained mixture. The pharmaceutical composition possesses excellent application values on diabetes.

The invention discloses a lipid-lowering Chinese medicinal composition and a preparation method thereof. The composition is prepared from the medicinal materials of panaxadiol saponins, Indian buead, oriental waterplantain rhizome, multiflower knotweed tuber, hawthorn, cassia seed, chicken gizzard membrane, malt, Chinese atractylodes, cassia twig and the like serving as raw materials. The invention further provides a preparation method of the lipid-lowering Chinese medicinal composition. By using the composition provided by the invention, the levels (P is less than 0.05) of total cholesterol and triglyceride in mouse and rat serums can be lowered remarkably, and an extremely remarkable lipid-lowering effect is achieved.

The invention relates to a medicinal composition for treating diabetes and its preparation method. The medicinal composition is characterized by being prepared from the following raw material drugs by weight: 8-15 parts of Berberis fruits, 4-6 parts of Spiraea alpina, 3-7 parts of lignum rhamnellae, 2-4 parts of Theloschestes flavicans, 3-5 parts of Cordia dichotoma fruits, and 2-4 parts of Aleuritopteris argentea Fee. The medicinal composition provided by the invention has good application value for treatment of diabetes.

The disclosure provides an antigenic peptide targeting the extracellular, but not the intracellular, form of CETP to reduce the level of LDL (including oxLDL and other derivatives of LDL) and increase the level of HDL. Accordingly, the disclosure provides a CETP vaccine to overcome the low immunogenicity of CETP and for long-term inhibition of CETP activity to prevent or treat oxLDL or other LDL derivative-related diseases/symptoms.

A traditional Chinese medicine composition for controlling blood lipid and/or body weight, its preparation method and application, the composition comprises Poria and peony. For lowering total cholesterol, triglycerides, LDL, uric acid levels in the body, increasing HDL levels in the body, and/or improving fatty liver symptoms.

The present invention relates to: a pharmaceutical composition for preventing or treating LDL cholesterol-related diseases, containing a ribosome-binding preparation; a food composition; and a method for preventing or treating LDL cholesterol-related diseases by using the composition. According to the present invention, the ribosome-binding preparation selectively increases the expression of an LDL receptor in intestinal epithelial cells so as to promote LDL absorption in blood and tissue, such that LDL level in the blood can be reduced, thereby being useful for preventing or treating various LDL cholesterol-related diseases including LDL hypercholesterolemia, hyperlipidemia, hypertension and apoplexy.

A peony seed oil and astaxanthin compound is mainly prepared from astaxanthin and peony seed oil, wherein the mass-volume ratio of the astaxanthin to the peony seed oil is 1-10 to 1000. The invention provides novel application of the peony seed oil and astaxanthin compound, specially application of the peony seed oil and astaxanthin compound in preparation in drugs and health-care products having fat lowering and antioxidant functions and application of the peony seed oil and astaxanthin compound in preparation in health-care products and functional beverages having fat lowering and antioxidant functions. The peony seed oil and astaxanthin compound has the fat lowering and antioxidant functions and the functions of improving serum SOD activity, reducing MDA content and lowering low density lipoprotein content.

The present invention refers to a device for treating cholesterol disorders for use in a method comprising administering at least one treatment regime including two or more rounds of plasmapheresis to a patient having abnormal total cholesterol, abnormal LDL levels and/or abnormal HDL levels prior to treatment. Treatment with said device results in decreased LDL levels in patients having abnormal LDL levels and increased HDL levels in patients having abnormal HDL levels. Each subsequent round of plasmapheresis is conducted weekly, but no more than twice per week.